Skip to main content

Animations

MJFF Publications

6231 - 6240 of 9145 Results
Title
Year
  • Year
  • 2014
  • 2018
  • 2020
  • 2016
  • 2015
  • 2020
  • 2021
  • 2019
  • 2021
  • 2021
  • Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease
    2014
    Summary Details
    RESTRICTED
    Title: Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.25859
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Impact of motor fluctuations on real-life gait in Parkinson’s patients
    Journal Name: Gait & Posture
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.gaitpost.2018.03.045
    Citation Count: 34
  • Summary Details
    OPEN
    Title: Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.51236
    Citation Count: 33
  • Summary Details
    OPEN
    Title: Nilotinib – Differentiating the Hope from the Hype
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-160904
    Citation Count: 32
  • Summary Details
    OPEN
    Title: Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3233/jpd-150570
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-191808
    Citation Count: 28
  • Summary Details
    OPEN
    Title: The commercial genetic testing landscape for Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.10.001
    Citation Count: 29
  • Summary Details
    OPEN
    Title: The Michael J. Fox Foundation for Parkinson’s Research Strategy to Advance Therapeutic Development of PINK1 and Parkin
    Journal Name: Biomolecules
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/biom9080296
    Citation Count: 26
  • Summary Details
    OPEN
    Title: Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28556
    Citation Count: 24
  • Summary Details
    OPEN
    Title: A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-212593
    Citation Count: 26
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.